Skip to content

Clinical trials

Completed Primary Myelofibrosis trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Primary Myelofibrosis Status: Completed Country / region: United States Clear all

244 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
200010
20013
200211
20037
200412
200518
200618
200717
200816
20099
201011
201115
20128
20137
20148
201510
20167
20178
20185
20192
20205
20217
20222
20241

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed244

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Fred Hutchinson Cancer Center26
M.D. Anderson Cancer Center18
National Cancer Institute (NCI)13
Case Comprehensive Cancer Center10
Incyte Corporation9
City of Hope Medical Center8
Sierra Oncology LLC - a GSK company8
John Mascarenhas5
Northwestern University5
Roswell Park Cancer Institute5

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Primary Myelofibrosis244
Myeloproliferative Disorders133
Precursor Cell Lymphoblastic Leukemia-Lymphoma124
Leukemia, Myeloid, Acute121
Leukemia, Lymphocytic, Chronic, B-Cell120
Multiple Myeloma109
Hodgkin Disease105
Lymphoma, Non-Hodgkin104
Myelodysplastic Syndromes104
Burkitt Lymphoma96

Trials

Showing 1 to 25 of 244. Each trial links to its page on Pharma Observatory.

144 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.